IL6 and myelodysplastic syndrome: Though the proliferative capacity of RUNX1S291fs/EZH2-null MDS cells was hampered, the study revealed that MDS bone marrow impairs normal hematopoietic cells via the activation of inflammatory cytokine responses, including the interleukin-6 (IL-6) pathway, which have been shown to impair normal HSCs in vivo, thereby promoting the survival and proliferation of MDS clones [61].